{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-25-000381","form_type":"8-K","ticker":"LIPO","cik":"0001347242","company_name":"LIPELLA PHARMACEUTICALS INC.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.405595+00:00","generated_at":"2026-05-25T17:05:01.811596+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"confidence":"high","headline":"Lipella raises $3.79M in third closing of Series B convertible preferred offering","bullets":["Sold 37,880 Series B convertible preferred shares at $100 each; gross proceeds $3.788M, net $3.124M after fees.","Over-allotment partially exercised; $385,500 from over-allotment included in gross proceeds.","Conversion price set at $3.00 or $3.13 per common share, subject to adjustment.","Spartan Capital earned $663,960 in fees, received 441,933 Series C shares and warrants for 125,833 common shares.","Second amendment makes Spartan's cash and stock compensation pro rata on total $7.2M across both offerings."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-25-000381","json":"https://secwatch.observer/filing/0001753926-25-000381.json","markdown":"https://secwatch.observer/filing/0001753926-25-000381.md","text":"https://secwatch.observer/filing/0001753926-25-000381.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347242/000175392625000381/0001753926-25-000381-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347242/000175392625000381/g084716_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T17:05:01.811596+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}